Biological E to start phase 3 clinical trials of its Covid-19 vaccine soon

The phase III clinical study, to be conducted in 15 sites across India, will evaluate the immunogenicity and safety of Biological E's vaccine candidate in 1,268 healthy subjects

Hyderabad-based vaccine maker Biological E. Limited (BE) got the Indian drug regulator's nod to start phase 3 clinical trial for its Covid-19 vaccine candidate.

Central Drugs Standard Control Organization's (CDSCO) Subject Expert Committee (SEC) approved the company's application to start phase 3 trials. NITI Aayog member V K Paul had said last week that the vaccine is expected to be ready for use sometime in August.

The phase III clinical study, to be conducted in 15 sites across India, will evaluate the immunogenicity and safety of Biological E’s SARS-CoV-2 COVID-19 vaccine for protection against Ciovid-19 disease in 1,268 healthy subjects in the